Financhill
Sell
47

ALEC Quote, Financials, Valuation and Earnings

Last price:
$1.18
Seasonality move :
14.01%
Day range:
$1.01 - $1.22
52-week range:
$0.87 - $6.78
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.30x
P/B ratio:
1.24x
Volume:
1.4M
Avg. volume:
872.6K
1-year change:
-77.5%
Market cap:
$117M
Revenue:
$100.6M
EPS (TTM):
-$1.26

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ALEC
Alector
$4.2M -$0.50 -72.54% -21.05% $5.26
ENOV
Enovis
$532.6M $0.66 5.56% 1731.46% $59.00
GERN
Geron
$52.3M -$0.03 5212.1% -66.5% $3.69
MDGL
Madrigal Pharmaceuticals
$181.2M -$3.47 985.75% -48.55% $421.93
RYTM
Rhythm Pharmaceuticals
$46.9M -$0.62 50.33% -12.27% $82.08
UTHR
United Therapeutics
$834.7M $7.92 12.23% 25.78% $388.18
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ALEC
Alector
$1.17 $5.26 $117M -- $0.00 0% 1.30x
ENOV
Enovis
$33.05 $59.00 $1.9B -- $0.00 0% 0.86x
GERN
Geron
$1.18 $3.69 $751.6M -- $0.00 0% 6.71x
MDGL
Madrigal Pharmaceuticals
$294.64 $421.93 $6.5B -- $0.00 0% 20.23x
RYTM
Rhythm Pharmaceuticals
$57.38 $82.08 $3.7B -- $0.00 0% 25.88x
UTHR
United Therapeutics
$301.42 $388.18 $13.6B 12.03x $0.00 0% 4.86x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ALEC
Alector
9.09% -0.451 7.69% 3.23x
ENOV
Enovis
34.64% 1.134 63.52% 0.99x
GERN
Geron
30.68% 1.799 11.72% 6.84x
MDGL
Madrigal Pharmaceuticals
14.24% 1.767 1.61% 5.41x
RYTM
Rhythm Pharmaceuticals
-- 1.841 -- 2.97x
UTHR
United Therapeutics
2.85% 1.506 1.44% 5.05x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ALEC
Alector
-- -$44.7M -89.62% -92.15% -1216.52% -$60.8M
ENOV
Enovis
$332.2M -$42.9M -18.51% -26.77% -8.62% -$44.9M
GERN
Geron
$38.4M -$16.7M -35.11% -46.58% -29.38% -$48M
MDGL
Madrigal Pharmaceuticals
$132.7M -$79.3M -43.17% -49.57% -50.96% -$88.9M
RYTM
Rhythm Pharmaceuticals
$29.1M -$47M -116.92% -116.92% -134.57% -$40.4M
UTHR
United Therapeutics
$701.9M $382.8M 18.69% 19.92% 54.08% $386.3M

Alector vs. Competitors

  • Which has Higher Returns ALEC or ENOV?

    Enovis has a net margin of -1101.55% compared to Alector's net margin of -10.02%. Alector's return on equity of -92.15% beat Enovis's return on equity of -26.77%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALEC
    Alector
    -- -$0.41 $104.1M
    ENOV
    Enovis
    59.45% -$0.98 $4B
  • What do Analysts Say About ALEC or ENOV?

    Alector has a consensus price target of $5.26, signalling upside risk potential of 349.57%. On the other hand Enovis has an analysts' consensus of $59.00 which suggests that it could grow by 78.52%. Given that Alector has higher upside potential than Enovis, analysts believe Alector is more attractive than Enovis.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALEC
    Alector
    5 1 1
    ENOV
    Enovis
    7 1 0
  • Is ALEC or ENOV More Risky?

    Alector has a beta of 0.757, which suggesting that the stock is 24.33% less volatile than S&P 500. In comparison Enovis has a beta of 1.583, suggesting its more volatile than the S&P 500 by 58.325%.

  • Which is a Better Dividend Stock ALEC or ENOV?

    Alector has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enovis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector pays -- of its earnings as a dividend. Enovis pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALEC or ENOV?

    Alector quarterly revenues are $3.7M, which are smaller than Enovis quarterly revenues of $558.8M. Alector's net income of -$40.5M is higher than Enovis's net income of -$56M. Notably, Alector's price-to-earnings ratio is -- while Enovis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector is 1.30x versus 0.86x for Enovis. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALEC
    Alector
    1.30x -- $3.7M -$40.5M
    ENOV
    Enovis
    0.86x -- $558.8M -$56M
  • Which has Higher Returns ALEC or GERN?

    Geron has a net margin of -1101.55% compared to Alector's net margin of -50.09%. Alector's return on equity of -92.15% beat Geron's return on equity of -46.58%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALEC
    Alector
    -- -$0.41 $104.1M
    GERN
    Geron
    96.96% -$0.03 $387M
  • What do Analysts Say About ALEC or GERN?

    Alector has a consensus price target of $5.26, signalling upside risk potential of 349.57%. On the other hand Geron has an analysts' consensus of $3.69 which suggests that it could grow by 212.5%. Given that Alector has higher upside potential than Geron, analysts believe Alector is more attractive than Geron.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALEC
    Alector
    5 1 1
    GERN
    Geron
    4 3 0
  • Is ALEC or GERN More Risky?

    Alector has a beta of 0.757, which suggesting that the stock is 24.33% less volatile than S&P 500. In comparison Geron has a beta of 0.765, suggesting its less volatile than the S&P 500 by 23.471%.

  • Which is a Better Dividend Stock ALEC or GERN?

    Alector has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector pays -- of its earnings as a dividend. Geron pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALEC or GERN?

    Alector quarterly revenues are $3.7M, which are smaller than Geron quarterly revenues of $39.6M. Alector's net income of -$40.5M is lower than Geron's net income of -$19.8M. Notably, Alector's price-to-earnings ratio is -- while Geron's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector is 1.30x versus 6.71x for Geron. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALEC
    Alector
    1.30x -- $3.7M -$40.5M
    GERN
    Geron
    6.71x -- $39.6M -$19.8M
  • Which has Higher Returns ALEC or MDGL?

    Madrigal Pharmaceuticals has a net margin of -1101.55% compared to Alector's net margin of -53.36%. Alector's return on equity of -92.15% beat Madrigal Pharmaceuticals's return on equity of -49.57%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALEC
    Alector
    -- -$0.41 $104.1M
    MDGL
    Madrigal Pharmaceuticals
    96.71% -$3.32 $828.6M
  • What do Analysts Say About ALEC or MDGL?

    Alector has a consensus price target of $5.26, signalling upside risk potential of 349.57%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of $421.93 which suggests that it could grow by 43.2%. Given that Alector has higher upside potential than Madrigal Pharmaceuticals, analysts believe Alector is more attractive than Madrigal Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALEC
    Alector
    5 1 1
    MDGL
    Madrigal Pharmaceuticals
    10 1 0
  • Is ALEC or MDGL More Risky?

    Alector has a beta of 0.757, which suggesting that the stock is 24.33% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.906, suggesting its less volatile than the S&P 500 by 190.598%.

  • Which is a Better Dividend Stock ALEC or MDGL?

    Alector has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALEC or MDGL?

    Alector quarterly revenues are $3.7M, which are smaller than Madrigal Pharmaceuticals quarterly revenues of $137.3M. Alector's net income of -$40.5M is higher than Madrigal Pharmaceuticals's net income of -$73.2M. Notably, Alector's price-to-earnings ratio is -- while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector is 1.30x versus 20.23x for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALEC
    Alector
    1.30x -- $3.7M -$40.5M
    MDGL
    Madrigal Pharmaceuticals
    20.23x -- $137.3M -$73.2M
  • Which has Higher Returns ALEC or RYTM?

    Rhythm Pharmaceuticals has a net margin of -1101.55% compared to Alector's net margin of -151.35%. Alector's return on equity of -92.15% beat Rhythm Pharmaceuticals's return on equity of -116.92%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALEC
    Alector
    -- -$0.41 $104.1M
    RYTM
    Rhythm Pharmaceuticals
    88.85% -$0.81 $163.1M
  • What do Analysts Say About ALEC or RYTM?

    Alector has a consensus price target of $5.26, signalling upside risk potential of 349.57%. On the other hand Rhythm Pharmaceuticals has an analysts' consensus of $82.08 which suggests that it could grow by 43.05%. Given that Alector has higher upside potential than Rhythm Pharmaceuticals, analysts believe Alector is more attractive than Rhythm Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALEC
    Alector
    5 1 1
    RYTM
    Rhythm Pharmaceuticals
    8 0 0
  • Is ALEC or RYTM More Risky?

    Alector has a beta of 0.757, which suggesting that the stock is 24.33% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals has a beta of 2.362, suggesting its more volatile than the S&P 500 by 136.233%.

  • Which is a Better Dividend Stock ALEC or RYTM?

    Alector has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector pays -- of its earnings as a dividend. Rhythm Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALEC or RYTM?

    Alector quarterly revenues are $3.7M, which are smaller than Rhythm Pharmaceuticals quarterly revenues of $32.7M. Alector's net income of -$40.5M is higher than Rhythm Pharmaceuticals's net income of -$49.5M. Notably, Alector's price-to-earnings ratio is -- while Rhythm Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector is 1.30x versus 25.88x for Rhythm Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALEC
    Alector
    1.30x -- $3.7M -$40.5M
    RYTM
    Rhythm Pharmaceuticals
    25.88x -- $32.7M -$49.5M
  • Which has Higher Returns ALEC or UTHR?

    United Therapeutics has a net margin of -1101.55% compared to Alector's net margin of 40.56%. Alector's return on equity of -92.15% beat United Therapeutics's return on equity of 19.92%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALEC
    Alector
    -- -$0.41 $104.1M
    UTHR
    United Therapeutics
    88.36% $6.63 $7B
  • What do Analysts Say About ALEC or UTHR?

    Alector has a consensus price target of $5.26, signalling upside risk potential of 349.57%. On the other hand United Therapeutics has an analysts' consensus of $388.18 which suggests that it could grow by 28.78%. Given that Alector has higher upside potential than United Therapeutics, analysts believe Alector is more attractive than United Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALEC
    Alector
    5 1 1
    UTHR
    United Therapeutics
    6 6 0
  • Is ALEC or UTHR More Risky?

    Alector has a beta of 0.757, which suggesting that the stock is 24.33% less volatile than S&P 500. In comparison United Therapeutics has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.76%.

  • Which is a Better Dividend Stock ALEC or UTHR?

    Alector has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector pays -- of its earnings as a dividend. United Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALEC or UTHR?

    Alector quarterly revenues are $3.7M, which are smaller than United Therapeutics quarterly revenues of $794.4M. Alector's net income of -$40.5M is lower than United Therapeutics's net income of $322.2M. Notably, Alector's price-to-earnings ratio is -- while United Therapeutics's PE ratio is 12.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector is 1.30x versus 4.86x for United Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALEC
    Alector
    1.30x -- $3.7M -$40.5M
    UTHR
    United Therapeutics
    4.86x 12.03x $794.4M $322.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Are We Heading Toward a Recession?
Are We Heading Toward a Recession?

Fears of a recession in 2025 grew at the end…

3 Recession-Proof ETFs to Invest in Now
3 Recession-Proof ETFs to Invest in Now

The U.S. gross domestic product (GDP) contracted 0.3% during the…

Is Butterfly Network the Best Small-Cap Stock?
Is Butterfly Network the Best Small-Cap Stock?

Brought to public trading by an SPAC merger in early…

Stock Ideas

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 40x

Alerts

Buy
60
RGC alert for May 10

Regencell Bioscience Holdings [RGC] is up 79.25% over the past day.

Buy
97
NGVC alert for May 10

Natural Grocers by Vitamin Cottage [NGVC] is up 30.26% over the past day.

Sell
38
ONTO alert for May 10

Onto Innovation [ONTO] is down 30.17% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock